A Study on Biochemical response and toxicity profile in very low, and intermediate risk prostate cancer individuals after stereotactic body radiotherapy

Introduction: Prostate cancer (PC) is the second most common cancer globally, with significant incidence in India. Various treatment options exist, but Stereotactic Body Radiotherapy (SBRT) is emerging as a precise method for managing very low, low, and intermediate-risk PC. This study aims to assess the efficacy and toxicity profile of SBRT in these patients. Methods: This prospective observational study at Omega Hospital, Hyderabad, involved 30 patients with localized prostate cancer treated with Stereotactic Body Radiotherapy (SBRT). Inclusion criteria included men over 18 years with a WHO performance status of 0-2. The study assessed PSA levels and toxicity profiles during and after treatment, following ethical approvals. Results: In this study, 40% of participants were under 65, 20% were over 76, and the rest were aged 66–75. Mean baseline PSA dropped significantly from 11.86 ng/dl to 0.71 ng/dl over 12 months post-SBRT. Most experienced grade 1 acute gastrointestinal and genitourinary toxicity, with no toxicity above grade 1 by three months. Conclusion: This study underscores SBRT’s effectiveness and safety in localized prostate cancer, showing significant PSA reduction and durable biochemical control. With mostly grade 1 acute gastrointestinal and genitourinary toxicity, SBRT proves to be a viable treatment option, offering effective cancer control and minimal impact on quality of life.